Tempol is under clinical development by Matrix Biomed and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Glioblastoma Multiforme (GBM) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Tempol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tempol overview

Tempol is under development for the radiation-induced skin toxicity, prevention of radiation-induced oral mucositis, chemotherapy-induced toxicities, treatment of neuropathy, ataxia-telangiectasia (Louis-Bar syndrome), recurrent glioblastoma multiforme, prostate cancer, doxorubicin induced toxicities, macular degeneration, cisplatin toxicities and paclitaxel induced toxicities. The drug candidate is administered orally and topically as a capsule and as a gel. MTS-01 (Tempol) is a piperidine nitroxide. Tempol is a membrane-permeable radical scavenger. It acts by targeting HIF-1 and HIF-2. It was under development for the treatment of alopecia and depression. 

It was under development for the treatment of ARDS, cytokine storm due to COVID-19 disease.

Matrix Biomed overview

Matrix Biomed is a biopharmaceutical company focused on the development of novel gene-based therapeutics for cancer treatments. The company developed TEMPOL, a compound that reaches every cell in the body and repairs damaged cellular environments thereby increasing mitochondria output and improving overall cellular function. Its pipeline products include MTS-01, a topical gel for prevention of radiation dermatitis; MTS-02 for rectal administration; MTS-10 is a water-based mouthwash formulation of TEMPOL for the prevention of oral mucositis; MBM-01 is a liquid formulation of TEMPOL being developed for the prevention of oral mucositis and other cisplatin and radiation induced toxicities; MBM-02, a gelatin capsule developed for the prevention various chemotherapeutic induced toxicities. Matrix Biomed is headquartered in Irvine, California, the US.

For a complete picture of Tempol’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.